Menu Breaking news sponsored byJohnson & Johnson Co (NYSE:JNJ) is ranked as a Buy using the approach of Louis Navellier for investing and his Portfolio Grader stock evaluator.  This represents no change from the previous week and is the same ranking JNJ has had from Portfolio Grader for 8 months.As one of the 782 companies in the GICS Health Care sector the company is a component of the 132 company Pharmaceuticals GICS industry group within this sector. JNJ's market value is $374.7 billion which places it in the top 10% of its industry group Portfolio Grader's current ranking for JNJ puts it 14 among the 132 companies in this industry group, giving it a well above-average position.Currently, Portfolio Grader ranks the Health Care sector number 9 among the 12 sectors in its universe putting it in the bottom quartile of all the GICS sectors. The Pharmaceuticals industry group is ranked 47 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.Johnson & Johnson has received above-average scores in 2 of the 8 fundamental areas analyzed by Portfolio Grader and average or below-average grades in 6 of the areas used in the ranking of company stocks.JNJ's operational scores are below the industry norms for sales growth, operating margin, and earnings growth. Scores for visibility of earnings are mixed, with a ranking for earnings surprises and earnings momentum that are worse than average, while the score for earnings revisions is better than average. JNJ's ranking for return on equity is much better than its industry group average but its grade for cash flow is below-average. These fundamental scores give Johnson & Johnson a position in the top half of the industry group. Portfolio Grader quantitatively views JNJ's shares using the Navellier Proprietary Quantitative Score. This metric looks at JNJ's shares from the aspect of risk/reward. This proprietary scoring methodology evaluates the relative value of JNJ's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Using this risk/reward calculation, the company currently scores well above-average in its industry group compared to its peers.Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'.  Explore the tool here.Commentary provided by UpTick Data Technologies.Article printed from InvestorPlace Media, https://investorplace.com/2017/11/johnson-johnsons-jnj-healthy-quant-score-keep-it-a-buy/.©2017 InvestorPlace Media, LLC

								About Us							
							  ·  													
								Press Center							
							  ·  													
								Resources							
							  ·  													
								Advisory Services							
							  ·  													
								Free Newsletters							
							  ·  													
								Free Reports							
							  ·  													
								Contact Us							
							  ·  													
								Advertise With Us							
							  ·  													
								Employment							
							  ·  													
								Privacy							
							  ·  													
								Terms and Conditions							
							  ·  													
								Disclosures and Disclaimers							
							  ·  													
								Media Sites							


								RSS							
							  ·  													
								Sitemap							

More On InvestorPlace:
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright © 2017 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.